Chronic Disease Flexible Coverage ActThis bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold.Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold. The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to includeangiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease;anti-resorptive therapy for individuals with osteoporosis or osteopenia;beta-blockers for individuals with congestive heart failure or coronary artery disease;blood pressure monitors for individuals with hypertension;inhaled corticosteroids and peak flow meters for individuals with asthma;insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes;international normalized ratio testing for individuals with liver disease or bleeding disorders;low-density lipoprotein testing for individuals with heart disease;statins for individuals with heart disease or diabetes; andselective serotonin reuptake inhibitors for individuals with depression. The bill provides statutory authority for the IRS's guidance.
Saving Seniors Money on Prescriptions ActThis bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.